People
A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.
Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.
Data security risks are growing as more and more clinical trials embrace telemedicine and other digital technologies.
With billions of doses of COVID-19 vaccines expected to be available by year’s end, and a global population of 7.8 billion, public health officials are scrambling to deliver the vaccines in ways that are equitable and effective.
Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.
As Moderna launched its Phase III clinical trial of its COVID-19 vaccine this week, a member of the company’s board of directors, Elizabeth “Betsy” Nabel, resigned to avoid any conflict of interest.
A multi-omics, multi-algorithm approach will unleash a new wave of understanding around Alzheimer’s disease and diagnosis, that in time, will make precision diagnostics practical, speakers predicted at the Alzheimer’s Association International Conference 2020.
Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.
As the world continues to navigate through the coronavirus pandemic, many biopharma companies are surging ahead with job creations. Check out these companies that have made recent job expansion announcements.
The vaccine was developed by Preston Estep, a former graduate student of Harvard University geneticist George Church.
PRESS RELEASES